biotech-dealmaker
(2)
Scott Peterson
Scott Peterson is the Chief Business Officer of T-Cypher Bio, an Oxford-based biotech building next-generation TCR therapeutics for solid tumors and autoimmune disease. A Harvard-trained PhD who started his career at the lab bench as a medicinal chemist at Merck, he crossed over to the deal side and spent two decades shaping pipelines and partnerships at Intarcia, Spero, and Dewpoint Therapeutics before taking the commercial helm at T-Cypher. He is the rare dealmaker who can read both a term sheet and a reaction mechanism.
Shafique Virani
Shafique Virani is a neurosurgeon-turned-biotech dealmaker who serves as Chief Business Officer of Noetik, an AI-native cancer therapeutics company in South San Francisco. He has spent two decades turning early-stage science into landmark partnerships, including one of the largest drug discovery deals ever struck at Recursion, and earlier built a neuroscience and rare-disease portfolio at Roche/Genentech that produced approved medicines like Risdiplam and Enspryng. At Noetik he is selling a new idea to pharma: not AI services, but licensable AI infrastructure for biology.